It is likely that in the protected mice immunized with the anti-DEC-205:16E5 conjugate, the CD8+ T cells were functioning efficiently as effector cells, due to the effective T cell help provided by the 16E5-specific CD4+ T cells, which allowed them to eliminate the tumor cells. Here, CD8A is linked to neoplasm.